AI could spot liver cancer types and predict survival without needle biopsy
NCT ID NCT07658586
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentiate between two common liver cancer types—hepatocellular carcinoma and intrahepatic cholangiocarcinoma—without needing a biopsy. It will also estimate how long patients might live without the cancer returning after tumor removal. The research involves at least 600 patients and uses past medical data to train and test the AI model.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Artificial intelligence model
What this could lead to
If successful, this AI system could help doctors diagnose liver cancer subtypes more accurately without invasive biopsies and better predict patient outcomes after surgery.
What could go wrong
This is a retrospective study using existing data, not a prospective trial. The AI model may not perform as well in real-world settings or on diverse patient populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University First Affiliated Hospital
Nanning, Guangxi, China